DRG International Company Timeline
2020
DRG Diagnostic developed two SARS-CoV-2 Antibody assays: 1) SARS-CoV-2 (RBD) Total Ab ELISA 2) SARS-CoV-2 (RBD) IgG ELISA
2019
DRG® develops and introduces Soluble Transferrin. DRG International receives the MDSAP Certification.
2018
DRG® develops and introduces Salivary Hepcidin.
2017
Dr. Cyril E. Geacintov, founder and owner of DRG International, passes away at the age of 87. Mrs. Elke Geacintov takes over as the President & CEO of DRG International. DRG® receives the ISO 13485 Certification.
2016
NEW WEBSITE LAUNCH !
2014
Small scale manufacturing and R&D begins in the DRG Headquarters in USA, managed by several additional staff
2013
Introduction for distribution of the DRG:HYBRiD-XLTM continues through international approval processes with great success Continued development of Elisa kits to utilize with DRG:HYBRiD-XLTM Expanded growth in several international markets including China
2012
New US Headquarters established in Springfield, New Jersey with expanded laboratory space and distribution DRG:HYBRiD-XLTM continues through international approval processes with great success
2011
Introduction of CA 72-4 (FDA Registration now underway)
2010
United States Patent Office issues two more patents to DRG International for development of Hepcidin diagnostic kits DRG International unveils the DRG: HYBRiD-XL® fully-automatic, random access analyzer for immunoassays and clinical chemistry to revolutionize laboratory procedures!
2009
Introduction to market of DRG® Renin, PLGF, Afamin, Anti-Amyloid, Cripto-1, CYR61, L1-Cam, and NOV Elisa kits
2008
United States Patent Office issues two patents to DRG International for development of Hepcidindiagnostic kits
2004
DRG® develops Tumor Markers, CA 72-4, CA 125, CA 15-3, CA 19-9, Cyfra21-1 and introduces Corticosterone andEstrone ELISAs
2003
DRG® develops and introduces the first worldwide Assay for the measurement of Hepcidin DRG® acquires Novum-Diagnostics in Dietzenbach and takes over production of more than 70 ELISAs for Infectious diseases in the DRG-Novum Branch Lab
2002
DRG® develops and introduces various Saliva -and DHEA –ELISAs
2000
DRG® develops and Introduces IGF1, IL-6,Cortisol- Saliva, Androstenedione ELISAs DRG® received certification for QM-System EN ISO9001:1994 DNVon October 27th Dade BehringTechnology is transferred to DRG® production of C5a and PAP – ELISAs
1999
DRG® develops and introduces Insulin, PAPP-A, and TGFßII ELISAs
1998
DRG® moves to a new building in Marburg, Germany DRG Instruments GmbH celebrates 25 years in Marburg, Germany
1997
DRG® develops and introduces Leptin, TGFß,and ß-HCG ELISAs
1996
DRG® develops and introduces Free Estriol ELISA
1995
DRG® develops and Introduces the first worldwide, non-radioactive C-Peptide and Proinsulin Assays
1994
DRG® develops and introduces DHEA-S, Progesterone, Testosterone, PMSG, and βGH ELISAs DRG® opens DRG Diagnostics Branch Office in Berlin, Germany
1993
DRG Techsystemsis founded in Moscow, Russa DRG® develops and introduces 17-OH-Progesterone ELISA
1992
DRG Sp.O.O. is founded in Brno, Czechoslovakia (Czech Rep.) DRG® develops and introduces AFP, HCG, FSH, Prolactin and LH
1991
DRG Biomed founded in St. Petersburg, Russia DRG® launches first neonatal entry of DRG®-ELISA:HPL
1990
DRG MEDTEK founded in Warsaw, Poland DRG® begins R&D and ELISA production in Marburg, Germany
1988
DRG AG founded in Zürich,Switzerland
1985
DRG® begins in-house R&D Operations
1982
DRG® expands in Eastern and Western Europe
1981
DRG® introduces the Mechanical Heart Valve on European Cardiac Surgery Market
1974
DRG Instruments GmbH moves to Marburg, Germany
1973
Distribution of RIA`s in Germany begins DRG Instruments GmbH is founded in Munich, Germany
1970
DRG International, Inc. was founded by Dr. C.E. Geacintov in New Jersey, USA DRG® enters market in Europe, USSR, Poland and Yugoslavia.